BioSpace News Archive

Veracyte, Inc. (Nasdaq: VCYT) will release its third quarter 2018 financial results after the close of market on Monday, October 29, 2018

Pulse Biosciences, Inc. announced today that the Compensation Committee of the company’s Board of Directors granted non-qualified stock options covering an aggregate of 20,750 shares of Pulse Biosciences common stock to four new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on October 15, 2018.

Shineco, Inc. (“Shineco” or the “Company"; NASDAQ: TYHT), a producer and distributor of Chinese herbal medicines, organic agricultural produce, specialized textiles, and other health and well-being focused plant-based products in China, announced today its financial results for the fiscal year ended June 30, 2018.

Two oral presentations will feature updated clinical data from an ongoing phase 2 clinical trial of sitravatinib in combination with nivolumab and a Phase 1b clinical trial of sitravatinib as a single agent

Trial results leveraging Cheetah Medical technology presented at the American Society of Anesthesiologists annual meeting in San Francisco

Allogene Therapeutics, Inc. today announced the closing of its previously announced initial public offering of 20,700,000 shares of its common stock, which includes 2,700,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $18.00 per share

Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on the Department of Health and Human Services’ proposal requiring drug companies to disclose the list price of prescription drugs in television ads:

Concordia International Corp. today announced that it has appointed pharmaceutical industry expert Frances Cloud to its board of directors. Ms. Cloud’s appointment will take effect on November 1, 2018.

Announces Release Date and Teleconference Call Details for 2018 Third Quarter Financial Results

The FDA continues to advance new policies, modernize our programs and advance opportunities for developing more targeted therapies.